Lisa Dreyer, Author at Pappas Capital

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

PONTE VEDRA, Fla., Dec. 11, 2025 -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics (“Veralox”). The acquisition immediately strengthens Cadrenal’s pipeline with a late-stage, first-in-class drug candidate targeting a critical immune signaling pathway. This acquisition addresses yet another underserved therapeutic opportunity in the $40 billion global anticoagulation market.

0-Homepage Feature / 0-Megaphone / Veralox Therapeutics - 12/11/2025

Horizon Quantum Computing Pte. Ltd. and dMY Squared Technology Group, Inc. Announce $110 Million PIPE Investment to Support Proposed Business Combination

SINGAPORE & LAS VEGAS--Dec. 5, 2025--Horizon Quantum Computing Pte. Ltd. (“Horizon Quantum”), a pioneer of software infrastructure for quantum applications, and dMY Squared Technology Group, Inc. (“dMY Squared”) (OTCQB: “DMYY”), a publicly traded special purpose acquisition company, announced that they have entered into subscription agreements with investors for a $110 million PIPE financing comprised of common equity, priced at the SPAC redemption price per share, to support the previously announced proposed business combination (the “Business Combination”) which is expected to close in the first quarter of 2026.

Horizon - 12/05/2025

Horizon Quantum Becomes First Quantum Software Company to Own and Operate Quantum Computer

SINGAPORE--Dec. 3, 2025--Horizon Quantum Computing Pte. Ltd., a pioneer of software infrastructure for quantum applications, today announced that it has completed the assembly and integration of a first quantum computer at its Singapore headquarters. The system is now fully operational. Assembled from components and operated directly by Horizon Quantum’s team, this system makes Horizon Quantum the first quantum software company to own and run a quantum computer.

Horizon - 12/05/2025

CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056)

SAN CARLOS, Calif.--Nov 10, 2025--CuraSen Therapeutics, Inc., a biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced encouraging results from a Phase 1 study with CuraAX (CST-3056). Data were presented by Gabriel Vargas, MD, PhD, chief medical officer, CuraSen Therapeutics, in both an oral and poster presentation at the 36^th International Symposium on the Autonomic Nervous System, held November 5-8 in Clearwater Beach, FL.

CuraSen Therapeutcis - 11/11/2025

CuraSen Therapeutics Doses First Patient with CuraAX (CST-3056) in Phase 2a Neurogenic Orthostatic Hypotension (nOH) Study

SAN CARLOS, Calif.--10/23/25--CuraSen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing drug candidates with broad applicability in neurodegenerative and neuropsychiatric diseases, today announced dosing of the first patient with CuraAX (CST-3056) in a Phase 2a proof-of-concept trial in neurogenic orthostatic hypotension (nOH). nOH is a serious condition characterized by a sudden drop in blood pressure when a person moves from sitting to standing, or from a supine position to sitting, that leads to debilitating dizziness, fainting, falls, hospitalizations and cognitive impairment due to reduced blood flow to the brain.

CuraSen Therapeutcis - 10/23/2025

Glycomine Initiates Dosing in a Global, Randomized, Placebo-Controlled Phase 2b Study of GLM101 for the Treatment of PMM2-CDG

SAN CARLOS, Calif., September 3, 2025 -- Glycomine, Inc. announced today that the first participant has been dosed in the global Phase 2b study, called POLAR. This randomized placebo-controlled multi-center clinical trial is designed to assess the safety and efficacy of GLM101, an investigational mannose-1-phosphate substrate replacement therapy for the treatment of phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG), a rare genetic disorder leading to serious neurological and multi-systemic impairments.

Glycomine - 09/04/2025

Enlaza Therapeutics Announces Strategic Collaboration with Vertex Pharmaceuticals to Develop War-Lock Drug Conjugates and T-Cell Engagers for Improved Conditioning and Certain Autoimmune Diseases

LA JOLLA, Calif., September 2, 2025 – Enlaza Therapeutics, the first covalent biologics platform company, today announced a multi-target drug discovery collaboration with Vertex Pharmaceuticals (Nasdaq: VRTX) to utilize Enlaza’s proprietary War-Lock™ technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.

Enlaza Therapeutics - 09/02/2025

Leriglitazone Marketing Authorization Application submitted for treatment of cerebral adrenoleukodystrophy has been validated by European Medicines Agency

Barcelona, Spain and Düsseldorf, Germany – 23 July 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders and Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of CNS disorders, today announce that the Marketing Authorization Application (MAA) for Minoryx’s lead candidate leriglitazone (NEZGLYAL®) has been submitted to the European Medicines Agency (EMA) for the treatment of paediatric and adult male patients with cerebral adrenoleukodystrophy (cALD). EMA has now validated the MAA file and it is under review by the Committee for Medicinal Products for Human Use (CHMP).

Minoryx - 07/23/2025

Minoryx receives a EUR 26.9m grant within the framework of the European IPCEI Med4Cure project for the continued development of leriglitazone in lethal orphan CNS diseases

Barcelona, Spain, 17 July 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders today announces that it has secured a EUR 26.9m non-dilutive grant for the development of its LERI4CNS project, which will validate leriglitazone for treating potentially lethal rare diseases affecting the CNS. The grant was given as part of the pan-European project “Important Project of Common European Interest (‘IPCEI') Med4Cure”, of which Minoryx Therapeutics is an Associated Member.

Minoryx - 07/17/2025

BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPVAssociated Oropharyngeal Squamous Cell Carcinoma

SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced data in a poster titled, “Phase 2 Trial of Ozuriftamab Vedotin (Oz-V), a Conditionally Binding CAB-ROR2-ADC, in Patients with Heavily Pretreated Squamous Cell Carcinoma of the Head and Neck.” The poster will be presented today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting at the McCormick Place Convention Center in Chicago, Illinois.

BioAtla - 06/02/2025

Investor Login

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class…